Navigation Links
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Date:8/21/2008

bout Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, gout, cancer and inflammatory diseases. We have five product candidates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, an NNRTI, which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it for clinical development. RDEA594, our lead product candidate for the treatment of gout, is being evaluated in a Phase 1 study. We are currently evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, and have completed a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it for clinical development.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015  Becton, Dickinson and Company (NYSE: ... commence offers to exchange all validly tendered and accepted ... a wholly owned subsidiary of BD, for notes to ... below. A Registration Statement on Form S-4 (the "Registration ... was filed with the Securities and Exchange Commission ("SEC") ...
(Date:3/26/2015)... , 26. März 2015  Die ... wird vom 1. April 2015 an Zulassungsanträge für ... abgebenden Apotheken annehmen. Seit dem Start des ... Verband über 275 .pharmacy-Domainnamen zugelassen, die für ... Zeiten beantragt wurden. Die NABP startete .pharmacy ...
(Date:3/26/2015)... -- Gelesis , a clinical stage biotechnology ... to induce weight loss and improve glycemic control, ... of shares of convertible preferred stock for gross ... of approximately $4 million of outstanding convertible promissory ... to support the continued clinical development of its ...
Breaking Medicine Technology:Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5Alle abgebenden Apotheken berechtigt, um ab dem 1. April 2015 .Pharmacy-Domainnamen zu beantragen 2Gelesis Closes $22M Equity Financing 2Gelesis Closes $22M Equity Financing 3
(Date:3/26/2015)... FL (PRWEB) March 26, 2015 ... the nation’s leading innovative specialty pharmacies, announces the ... position of Vice President of Pharmaceutical Relations. In ... beneficial connections with our pharmaceuticals partners and providing ... in support of BioPlus’ expansion. , “Over ...
(Date:3/26/2015)... In the key developed markets, the hypertension ... is set to decrease through 2020 at a negative CAGR ... expected up to 2017 at a 2.6% CAGR and a ... to the surging penetration of fixed-dose combination drugs like Azor, ... Benicar HCT, and Tekamlo), a hike in the prevalence population ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Leading ... brand-new, state-of-the-art company website: http://www.metabolicnutrition.com . ... revamped website creates a user-friendly experience for consumers ... , The new, enhanced Metabolic Nutrition website ... about the company’s diverse line of products, conveniently ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Zane Benefits, ... businesses, announced a new eBook, “The Comprehensive Guide To ... eBook, interviewing is the most important aspect of the ... they are hiring the right way, possibly resulting in ... be an arduous undertaking, yet it’s essential to the ...
(Date:3/26/2015)... 26, 2015 LinkToBanking, a Preferred ... names Tom Fleming as Chairman of the Board ... effective immediately. With their combined knowledge and ... industry, Mr. Fleming and Mr. Casares will provide ... to cannabis related businesses. , About Tom Fleming, ...
Breaking Medicine News(10 mins):Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:Metabolic Nutrition Launches Sleek New Website with New Features and Enhanced Consumer Information 2Health News:Zane Benefits Announces: New eBook: The Comprehensive Guide To Interviewing For Your Small Business 2Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 2Health News:Tom Fleming named Chairman of the Board and Robert Casares as Vice-Chairman of the Board of LinkToBanking 3
... toll was so overwhelming that steam shovels were brought in ... trains commandeered to transport dead soldiers and priests could be ... threat of another flu pandemic looming in the not too ... preparations for it mortuary specialists are once more faced with ...
... babies much before the full term are administered steroids. ... the University of Adelaide , has found that subjecting ... babies by reducing potential breathing difficulties during delivery. ... babies from the Adelaide Women's and Children's Hospital. Research ...
... to introduce a system in which the GPs would be graded ... government to vote in favor for the new scheme of grading ... According to this the surgeries were to be inspected by doctors, ... one to three. It was a modification of the accreditation scheme. ...
... which is already running in a loss would have to pay ... are not in a position // to fulfil the commitment to ... health services. ,The trusts in the south of England ... ?20bn scheme under a deal with Japanese firm Fujitsu. But the ...
... Cheltenham Science Festival that it plans to send a ... //a research into the effects of low oxygen levels, ... for Aviation, Space and Extreme Environment Medicine at the ... will be conducting the research along with researchers around ...
... In a breakthrough move against HIV drug resistance, scientists have now ... that is the first in a new class of HIV drug ... Caspsid, a key viral protein from its precursor protein,this group of ... acid, and interferes with the production of the capsid conical ...
Cached Medicine News:Health News:What to do with the Dead if a Flu Outbreak Happens? 2Health News:Already Short Staffed And In Deficit NHS Fails To Supply Staff For IT Project 2Health News:Mount Everest to be Site of Research into Hypoxia 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: